Resverlogix Corp. (TSE:RVX – Get Free Report) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as C$0.04 and last traded at C$0.04, with a volume of 1445 shares changing hands. The stock had previously closed at C$0.05.
Resverlogix Trading Up 12.5 %
The company has a market capitalization of C$8.91 million, a P/E ratio of -2.23 and a beta of 0.71. The company has a 50-day simple moving average of C$0.05 and a 200 day simple moving average of C$0.05. The company has a debt-to-equity ratio of -10.95, a quick ratio of 0.04 and a current ratio of 0.13.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Read More
- Five stocks we like better than Resverlogix
- What Are Earnings Reports?
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- The 3 Most Talked About Investments on WallStreetBets Right Now
- What is a Bond Market Holiday? How to Invest and Trade
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
